Tomorrow, LXRX will be sharing Phase 2b topline results of their LX9211 non-opioid analgesic for DPNP.
LXRX stock has declined 38% since their earnings miss & divestiture of Sotagliflozin in Nov '24.
With significant float lock up, high short-interest, and a potentially positive readout, LXRX is poised for a major move to the upside.
PT1: $0.96
PT2: $1.08
Above $1.38 has potential to squeeze to $1.90.
LXRX stock has declined 38% since their earnings miss & divestiture of Sotagliflozin in Nov '24.
With significant float lock up, high short-interest, and a potentially positive readout, LXRX is poised for a major move to the upside.
PT1: $0.96
PT2: $1.08
Above $1.38 has potential to squeeze to $1.90.
Trading ditutup: stop tercapai
okay, i learned that i cant do fundamental analysis. sticking to TA lmao 
just practicing & learning
Pernyataan Penyangkalan
Informasi dan publikasi ini tidak dimaksudkan, dan bukan merupakan, saran atau rekomendasi keuangan, investasi, trading, atau jenis lainnya yang diberikan atau didukung oleh TradingView. Baca selengkapnya di Ketentuan Penggunaan.
just practicing & learning
Pernyataan Penyangkalan
Informasi dan publikasi ini tidak dimaksudkan, dan bukan merupakan, saran atau rekomendasi keuangan, investasi, trading, atau jenis lainnya yang diberikan atau didukung oleh TradingView. Baca selengkapnya di Ketentuan Penggunaan.